Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Multi-Application Platform for Non-Invasive Body and Skin Treatments Venus NOVA is the first product clearance from the Company's new R&D strategy GlobeNewswire November 10, 2025 TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”), a global leader in […]

Tyson Foods Reports Fourth Quarter And Fiscal 2025 Results Achieves Year-Over-Year Growth in Sales, Adjusted Operating Income and Adjusted EPS GlobeNewswire November 10, 2025 SPRINGDALE, Ark., Nov. 10, 2025 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world's largest food companies and a recognized leader in protein with leading brands including Tyson,

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 GlobeNewswire November 10, 2025 Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Cytokinetics,

Bluejay Therapeutics' Brelovitug (BJT-778) Monotherapy Achieved 100% Virologic Response and up to 82% Combined Endpoint of Virologic Response and ALT Normalization at Week 48 in Phase 2 Study in Chronic Hepatitis D (CHD) GlobeNewswire November 10, 2025 All brelovitug dose regimens studied were well tolerated Results will be presented at The Liver Meeting(R) 2025 of

FreightCar America, Inc. Reports Third Quarter 2025 Results GlobeNewswire November 10, 2025 Delivered 42% revenue growth year-over-year Strong gross margins of 15.1%, expansion of 80 basis points Reaffirming Adjusted EBITDA guidance for full year CHICAGO, Nov. 10, 2025 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and

SUNation Energy Announces 2025 Third Quarter Results and Reiterates 2025 Full Year Financial Guidance GlobeNewswire November 10, 2025 Q3 2025 Select Highlights Sales Increased 29% to $19.0 Million Gross Profit Rose to $7.2 Million; Gross Margin Improved to 38% Net Loss Narrowed to $0.4 Million Adjusted EBITDA Improved to $898,000 Unrestricted Cash Rose to $5.4

Surgery Partners, Inc. Announces Third Quarter 2025 Results GlobeNewswire November 10, 2025 BRENTWOOD, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights (All comparisons

Pixalate's October 2025 United States Publisher Rankings: Top Mobile 'Sports' Apps For Programmatic Advertising Traffic Quality in the Apple App Store and Google Play Store GlobeNewswire November 10, 2025 According to Pixalate's October 2025 rankings, 'CBS Sports Fantasy', 'ESPN: Live Sports & Scores, and 'FotMob – Soccer Live Scores' were the top three Apple App

FG Nexus to Present at the 2025 Cantor Crypto & AI/Energy Infrastructure Conference GlobeNewswire November 10, 2025 Charlotte, NC, Nov. 10, 2025 (GLOBE NEWSWIRE) — FG Nexus (Nasdaq: FGNX, FGNXP) (the “Company” or “FG Nexus”), today announced that management will participate at the Cantor Crypto & AI/Energy Infrastructure Conference on November 10-12th, 2025 at the

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) GlobeNewswire November 10, 2025 Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concern In HS, over 4 weeks of therapy,